# COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question

**Authors:** Chris R. Triggle, Ross MacDonald

PMC · DOI: 10.3390/v17070881 · 2025-06-23

## TL;DR

This paper discusses the evaluation of three drugs for treating COVID-19, highlighting the debate between repurposing existing drugs and developing new ones.

## Contribution

The paper provides an analysis of the scientific evidence and controversies surrounding the repurposing of hydroxychloroquine, ivermectin, and remdesivir for COVID-19.

## Key findings

- Hydroxychloroquine, ivermectin, and remdesivir were considered as repurposed drug candidates for treating COVID-19.
- Scientific evidence for these drugs' efficacy was debated alongside public demand and political influences.
- Repurposing existing drugs can accelerate treatment development by skipping preclinical studies.

## Abstract

On 11 March 2020, the World Health Organisation (WHO) declared a global pandemic caused by the SARS-CoV-2 coronavirus that earlier in February 2020 the WHO had named COVID-19 (coronavirus disease 2019). There were neither drugs nor vaccines that were known to be effective against the virus, stimulating an urgent worldwide search for treatments. An evaluation of existing drugs by ‘repurposing’ was initiated followed by a transition to de novo drug discovery. Repurposing of an already approved drug may accelerate the introduction of that drug into clinical use by circumventing early, including preclinical studies otherwise essential for a de novo drug and reducing development costs. Early in the pandemic three drugs were identified as repurposing candidates for the treatment of COVID-19: (i) hydroxychloroquine, an anti-malarial also used to treat rheumatoid arthritis and lupus; (ii) ivermectin, an antiparasitic approved for both human and veterinary use; (iii) remdesivir, an anti-viral originally developed to treat hepatitis C. The scientific evidence, both for and against the efficacy of these three drugs as treatments for COVID-19, vied with public demand and politicization as unqualified opinions clashed with evidence-based medicine. To quote Hippocrates, “There are in fact two things, science and opinion; the former begets knowledge, the latter ignorance”.

## Linked entities

- **Chemicals:** hydroxychloroquine (PubChem CID 3652), remdesivir (PubChem CID 121304016)
- **Diseases:** COVID-19 (MONDO:0100096), rheumatoid arthritis (MONDO:0008383), lupus (MONDO:0004670)

## Full-text entities

- **Diseases:** rheumatoid arthritis (MESH:D001172), COVID-19 (MESH:D000086382), hepatitis C. (MESH:D019698), lupus (MESH:D008180)
- **Chemicals:** remdesivir (MESH:C000606551), ivermectin (MESH:D007559), hydroxychloroquine (MESH:D006886)
- **Species:** Homo sapiens (human, species) [taxon 9606], Gammacoronavirus (genus) [taxon 694013], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12298200/full.md

---
Source: https://tomesphere.com/paper/PMC12298200